Press Releases :: Nighthawk Biosciences, Inc. (SCPX)

Jan 26, 2016 7:00am EST

Heat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase 2 Bladder Cancer Trial at the Phacilitate Immunotherapy World Conference

Jan 07, 2016 4:14pm EST

Heat Biologics to Present at Biotech Showcase 2016

Dec 01, 2015 7:00am EST

Heat Biologics Appoints Timothy Creech as Chief Financial Officer

Nov 18, 2015 7:00am EST

Heat Biologics Selected as One of Informa's 2015 Top 10 Immuno-Oncology Companies to Watch

Nov 06, 2015 7:00am EST

Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 03, 2015 8:00am EST

Results of Heat Biologics' HS-410 Phase 1 Safety Trial in Non-Muscle Invasive Bladder Cancer to be Presented at SITC Annual Meeting

Oct 30, 2015 7:00am EDT

Heat Biologics Releases Third Quarter 2015 Financial Results

Oct 14, 2015 7:00am EDT

Heat Biologics Expands Scientific and Clinical Advisory Board With Appointments of Drs. Holbrook Kohrt and Kapil Dhingra

Oct 08, 2015 7:00am EDT

Heat Biologics Completes Patient Enrollment for Randomized Arms of Its Phase 2 HS-410 Bladder Cancer Trial

Oct 07, 2015 7:00am EDT

Heat Biologics to Participate in the Annual Prostate Cancer Foundation Scientific Retreat

rss_feed News RSS